These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Blinatumomab for Acute Lymphoblastic Leukemia. Kantarjian H; Jabbour E; Topp MS N Engl J Med; 2017 Jun; 376(23):e49. PubMed ID: 28591537 [No Abstract] [Full Text] [Related]
15. Limits on Medicare's ability to control rising spending on cancer drugs. Bach PB N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475 [No Abstract] [Full Text] [Related]
16. Blinatumomab for the treatment of B-cell lymphoma. Oak E; Bartlett NL Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952 [TBL] [Abstract][Full Text] [Related]
17. Blinatumomab for the treatment of acute lymphoblastic leukemia. Kaplan JB; Grischenko M; Giles FJ Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529 [TBL] [Abstract][Full Text] [Related]
18. Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia. Turner J; Schneider SM Clin J Oncol Nurs; 2016 Apr; 20(2):165-8. PubMed ID: 26991709 [TBL] [Abstract][Full Text] [Related]
19. Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL). Friberg G; Reese D Ann Oncol; 2017 Aug; 28(8):2009-2012. PubMed ID: 28379283 [No Abstract] [Full Text] [Related]